Amgen, one of the world’s leading biotechnology companies, has announced that it has completed its acquisition of Horizon Therapeutics, a Dublin-based company that specializes in rare, autoimmune and severe inflammatory diseases. The deal, which was first announced in December 2022, is valued at approximately $27.8 billion and represents the biggest buyout in the biopharma sector this year1.
The acquisition will strengthen Amgen’s portfolio of innovative medicines that make a significant difference for patients suffering from serious diseases. Amgen will gain access to Horizon’s first-in-class products such as TEPEZZA, KRYSTEXXA and UPLIZNA, which treat rare inflammatory conditions such as thyroid eye disease, chronic gout and neuromyelitis optica spectrum disorder1.
“Today marks an exciting milestone as we welcome Horizon employees to Amgen and begin working together to serve even more patients around the world suffering from serious illnesses,” said Robert A. Bradway, Amgen’s chairman and chief executive officer1. “We have strong momentum in our core business and the addition of Horizon will further position Amgen as a leader across a broader range of diseases.”
The deal is expected to accelerate Amgen’s revenue growth and be accretive to its non-GAAP earnings per share from 2024. Amgen expects to provide updated FY 2023 guidance during its third quarter earnings call1.